1.
Haznedaroglu IC. MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML). Mediterr J Hematol Infect Dis [Internet]. 2013 Dec. 31 [cited 2022 Jan. 28];6(1):e2014009. Available from: https://www.mjhid.org/index.php/mjhid/article/view/2014.009